Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro

摘要

The present study aimed to investigate the effects of octreotide (OCT) on the reversal of resistance of cisplatin-resistant cancer cells and on enhancement of the cisplatin sensitivity of cancer cells. The 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide method and flow cytometry were used to investigate the effect of cisplatin, OCT or the combination of these two compounds on the proliferation and apoptosis of SKOV3/DDP cells. Real-time, quantitative RT-PCR was used to detect the mRNA expression of SSTR2, MDR1, MRP2, GST-π and EGFR in SKOV3/DDP cells following OCT treatment. At the concentration of 2.5–20 μg/ml, OCT significantly reduced the IC50 value (P<0.05) and promoted apoptosis (P<0.05) in the SKOV3/DDP cells in response to cisplatin. The synergistic effect of OCT and cisplatin on SKOV3/DDP cell proliferation was observed. SSTR2 was expressed on the SKOV3/DDP cell surface. OCT increased GST-π expression (P<0.05) and reduced MRP2 and EGFR expression (P<0.05) in a dose-dependent manner. However, it had no effect on the expression of MDR1 (P>0.05). It is suggested that OCT inhibits ovarian cancer proliferation and promotes apoptosis, via the cell surface expression of SSRT2, and reverses cisplatin resistance through the inhibition of MRP2 and EGFR expression.